MRSN

MRSN

USD

Mersana Therapeutics Inc. Common Stock

$8.160-0.905 (-9.983%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$9.065

Máximo

$9.065

Mínimo

$8.000

Volume

0.03M

Fundamentos da empresa

Capitalização de mercado

40.7M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.07M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $5.21Atual $8.160Máximo $70.75

Notícias relacionadas

Analyst Upgrades

Truist Securities Maintains Buy on Mersana Therapeutics, Adjusts Price Target To $36 from $250

Truist Securities analyst Asthika Goonewardene maintains Mersana Therapeutics with a Buy, Adjusts Target to $36 from $250

Ver mais
Truist Securities Maintains Buy on Mersana Therapeutics, Adjusts Price Target To $36 from $250
Analyst Upgrades

Guggenheim Maintains Buy on Mersana Therapeutics, Lowers Price Target to $30

Guggenheim analyst Michael Schmidt maintains Mersana Therapeutics with a Buy and lowers the price target from $125 to $30.

Ver mais
Guggenheim Maintains Buy on Mersana Therapeutics, Lowers Price Target to $30
Earnings Call Transcripts

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

Ver mais
Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript
GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion

Ver mais
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
GlobeNewswire

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers

Ver mais
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.